We are live on
!
Find out more
AbCellera Biologics
ABCL
ABCL
144 hedge funds and large institutions have $371M invested in AbCellera Biologics in 2025 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 50 increasing their positions, 38 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
128% more call options, than puts
Call options by funds: $7.01M | Put options by funds: $3.07M
32% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 38
15% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 27
2% more funds holding
Funds holding: 141 → 144 (+3)
1.4% more ownership
Funds ownership: 34.81% → 36.22% (+1.4%)
29% less capital invested
Capital invested by funds: $525M → $371M (-$154M)
Holders
144
Holders Change
+3
Holders Change %
+2.13%
% of All Funds
1.75%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
50
Reduced
38
Closed
27
Calls
$7.01M
Puts
$3.07M
Net Calls
+$3.94M
Net Calls Change
-$417K
Top Buyers
| 1 |
UBS AM
Chicago,
Illinois
|
+$35.2M |
| 2 |
Goldman Sachs
New York
|
+$18.3M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$9.13M |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$4.76M |
| 5 |
Jane Street
New York
|
+$4.46M |
Top Sellers
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$52.4M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$13.1M |
| 3 |
Renaissance Technologies
New York
|
-$4.34M |
| 4 |
DnB Asset Management
Oslo,
Norway
|
-$3.3M |
| 5 |
Millennium Management
New York
|
-$2.93M |
